HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 11/13/2012 -- Titanium Metals C (NYSE:TIE) is very active today and traded between $16.43 - 16.56 with total traded volume of 36431152 shares. At a current price of 16.50, TIE is +4.93 - +42.61% from the previous close of $11.57. Moreover, At Current Market Price, TIE is in distance of +34.41% from its 50-day Moving Average price of $12.2755 and +35.17% from its 200-day Moving Average price of $12.2064. Titanium Metals Corp. – Shares in the producer of titanium melted and mill products are up better than 40% on Monday after Precision Castparts Corp. announced late on Friday it will buy Titanium Metals Corp. for $16.50 a share. Options traders who purchased upside calls as recently as Friday afternoon are, in some cases, enjoying massive gains in the value of their options contracts today given the move in the stock.
Are these stocks a buy or sell? Free Sign Up Here For Free Guide
Sarepta (NASDAQ:SRPT) is rising after JMP Securities analyst Liisa Bayko wrote that a competing drug will not likely be approved until 2014 or 2015. Dispersen, a Duchenne muscular dystrophy treatment developed by GlaxoSmithKline (GSK) and Prosensa, is not expected to be approved until 2014-2015, GlaxoSmithKline announced this weekend, according to Bayko. The delay will remove an overhang from Sarepta, the analyst believes. Moreover, Prosensa has had some difficulties with its drug, added, Bayko. Shares of Sarepta can rise significantly over the long-term and short-term, and investors should own the shares into 2013, she wrote. In mid-morning trading, Sarepta jumped $2.19, or 9.58%, to $24.94.Shares of Sarepta Therapeut (NASDAQ:SRPT) are trading at $27.13 and is +87.88% from its 50-day Moving Average price of $14.44 and +278.01% from its 200-day Moving Average price of $7.1771. The average trading volume is 1781180 shares and its market capitalization is $619.2M.
Is SRPT Showing Any Sign of Buy At The Current Market Price? Get Our Free Trend Analysis Here
Shares of Myrexis (NASDAQ:MYRX), the Salt Lake City, UT biopharmaceutical company, rose 17.95% Monday on 110 times average volume. Myrexis announced Friday that its Board of Directors has determined, after extensive and careful consideration of potential strategic alternatives, that it is in the best interests of the Company and its shareholders to dissolve the Company and liquidate its assets. In connection with the dissolution and liquidation, which is subject to shareholder approval, the Company intends to distribute to its shareholders all available cash, except such cash as is required for paying or making reasonable provision for known and potential liabilities and other obligations of the Company. Myrexis, Inc (NGM:MYRX) is +0.42 - +17.95% from the previous close of $2.34. It traded between $2.69 - 2.76 with total traded volume of 5848629 shares. At Current Market Price, MYRX is in distance of +14.55% from its 50-day Moving Average price of $2.4094 and +8.49% from its 200-day Moving Average price of $2.5441.
How Should Investors React to MYRX Now? Find Out Here
Jefferies Group, (NYSE:JEF) is very active today and traded between $15.81 - 17.32 with total traded volume of 21559980 shares. At a current price of 16.27, JEF is +2.00 - +14.02% from the previous close of $14.27. Moreover, At Current Market Price, JEF is in distance of +11.59% from its 50-day Moving Average price of $14.58 and +19.31% from its 200-day Moving Average price of $13.637. Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Jefferies Group, Inc. (“Jefferies” or the “Company”) (JEF) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Leucadia National Corp. (LUK) (“Leucadia”) in a stock-for-stock deal valued at approximately $2.6 billion. Under the terms of the proposed transaction, Jefferies’ stockholders will receive 0.81 of a share of Leucadia stock for each share of Jefferies common stock they hold. The transaction values the proposed consideration at approximately $17.66 per share, based on Friday closing price, while according to Yahoo! Finance, at least one financial analyst has set a price target of $19 for Jefferies.
Collect The Full Research Report On JEF For Free: CLICK HERE
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)